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A percentage of celiac disease (CD) patients develop refractory type-2 disease (RCD2), a
condition associated with increased risk of enteropathy-associated T-cell-lymphoma (EATL)
and without therapeutic option. Therefore, we profiled the miRNome in series of peripheral
T-cell lymphomas (PTCLs), CD, RCD1 or 2 and in the murine interleukin-15 (IL15)-transgenic
(TG) model of RCD. The transcriptome was analyzed in 18 intestinal T-cell lymphomas (ITLs).
Bioinformatics pipelines provided significant microRNA (miRNA) lists and predicted targets
that were confirmed in a second set of patients.
Our data show that ITLs have a unique miRNA profile with respect to other PTCLs. The
c-MYC regulated miR-17/92 cluster distinguishes monomorphic epitheliotropic ITL (MEITL)
from EATL and prognosticates EATL outcome. These miRNAs are decreased in IL15-TG
mice upon Janus kinase (JAK) inhibition. The random forest algorithm identified a signature
of 38 classifier miRNAs, among which, the miR-200 andmiR-192/215 families were progres-
sively lost in RCD2 and ITL-CD, whereasmiR-17/92 andC19MCmiRNAswere up-regulated.
Accordingly, SMAD3,MDM2, c-Myc and activated-STAT3were increased in RCD2 and EATL
tissues while JAK inhibition in IL15-TG mice restored their levels to baseline.
Our data suggest that miRNAs circuit supports activation of STAT3 and c-Myc oncogenic
signaling in RCD2, thus contributing to lymphomagenesis. This novel understanding might
pave the way to personalized medicine approaches for RCD and EATL.
Introduction
Celiac disease (CD) represents the most common autoimmune enteropathy in Western countries with a
prevalence of approximately 1:100 individuals. The only available therapy is the gluten-free diet (GFD)
that usually resolves symptoms and reverts duodenal damage. However, a minority of CD patients (ap-
proximately 5%) can develop severe and life-threatening complications such as refractory CD (RCD) and
enteropathy-associated T-cell lymphoma (EATL) [1].
Refractory celiac sprue is defined by persistent malabsorptive symptoms and villous atrophy despite
strict adherence to a GFD for at least 12 months. There are two types of RCD, with type 2 being more
aggressive. Type 1 RCD (RCD1) shows a normal intraepithelial lymphocyte phenotype with surface
expression of CD3 and CD8 markers and a polyclonal T-cell receptor (TCR) repertoire. Conversely,
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RCD2 is characterized by the presence of an aberrant intraepithelial T-cell clone (IEL), which lacks surface CD3 ex-
pression but shows intracytoplasmic CD3 expression. Moreover, aberrant IELs frequently show TCR clonality [2,3].
The majority of patients with RCD2 (>60%) develop intestinal lymphoma within 5 years from the initial diagnosis,
and this condition is now considered a malignant precursor of EATL [1,3]. Both RCD2 and EATL have a dismal
prognosis with a mortality rate of approximately 80%. Moreover, the role of surgery as a curative strategy is lim-
ited due to complications such as perforation and multifocal nature of the diseases. Despite the known contribution
of the individual’s genetic background, i.e. the expression of HLA-DQ2 or HLA-DQ8 molecules as an important
susceptibility factor for CD, the pathogenetics of CD and related complications are poorly understood. To date, the
surveillance of RCD patients is performed using highly invasive and poorly reproducible techniques, such as cap-
sule endoscopy or device-assisted enteroscopy with or without duodenal mucosal biopsy [3]. Finally, while TCRγ
clonality and flow-cytometric evidence of the aberrant T-cell clones being diagnostic hallmarks for RCD2, [1] these
are not useful biomarkers for patients’ prognostication, follow-up or therapy decision-making. A pathogenic role for
interleukin-15 (IL15) has been established in CD and IL15 up-regulation in the duodenal mucosa of CD subjects is
now considered a feature of active disease [4]. IL15 influences every phase of CD, from the initial loss of oral tol-
erance to gluten, to loss of immune cell homeostasis and epithelial cell killing, eventually sustaining the expansion
of the aberrant intraepithelial T lymphocytes in RCD2 disease. IL15 effects are pivotally dependent on the family of
Janus kinases (JAKs). It has been shown that JAK inhibition through Tofacitinib, a pan-JAK inhibitor (JAKi), reverts
the intestinal damage in the transgenic (TG) mouse model that overexpresses IL15 specifically in the enterocytes
(T3b-hIL-15 Tg mice) [5,6]. We have previously characterized the microRNA (miRNA) profiles in different CD phe-
notypes, highlighting that the miR-192/215 family is down-regulated in patients with active CD in spite of GFD [7].
In the present study, extending our previous observation, we have profiled the miRNome in the IL15 TG mice
treated or not with the pan-JAKi Tofacitinib and in a series of intestinal T-cell lymphomas (ITLs), RCD and CD to
gain compelling evidence of miRNA dysregulation during lymphomagenesis of aberrant IELs. Moreover, we aimed
to identify molecular signatures with prognostic relevance that may support clinicians in designing a personalized
medicine approach for RCD patients.
Materials and methods
Peripheral T-cell lymphoma samples
A series consisting of 21 peripheral T-cell lymphoma (PTCL) not otherwise specified (PTCL-NOS), six ALK-positive
and four ALK-negative anaplastic large cell lymphomas (ALCLs), ten angioimmunoblastic T-cell lymphoma (AITL)
have been previously described [8] and total RNA was available for this study.
Intestinal lymphoma samples
A series of 23 ITLs was retrieved from the archives of Sant’Orsola Hospital (Bologna, Italy) and immunophenotyped
according to current WHO guidelines [9]. Briefly, the antibody panel included CD2, CD3, CD4, CD5, CD7, CD8,
CD20, CD30, CD56, CD103,βF1, TIA1, Perforin, Granzyme B and KI67. Moreover, TCR clonality and Epstein–Barr
virus (EBV) presence were assessed and recorded as well. According to this panel, ITL were categorized as EATL
(n=14), monomorphic epitheliotropic ITL (MEITL; n=7) or EBV-positive extranodal nasal-type NK/T-cell lym-
phoma (EBVpos-ENKL; n=2). This latter type of lymphoma was excluded from the analysis of intestinal lymphoma
samples. Among EATL or MEITL, 12 (86%) and 1 (14%) patients had history of CD. For 18 patients, survival data
were available. Samples characteristic are detailed in Table 1. A second cohort of seven EATL originated in celiac pa-
tients (from Fondazione IRCCS Ca’ Granda Hospital) was used for target expression analysis (Supplementary Table
S1).
CD samples
Duodenal biopsies from an initial set of patients with CD at first diagnosis (n=5; CD), patients with CD under GFD
with (n=5; CD in remission, r-CD) or without (n = 5; active CD, a-CD) normalization of villous atrophy, refractory
type 1 CD (n = 4; RCD1) or with refractory type 2 CD (n = 5; RCD2) were retrieved from the archives of the
Division of Pathology of Fondazione IRCCS Ca’ Granda (Milan, Italy) or IRCCS San Matteo (Pavia, Italy) hospitals
and used for miRNA profiling. Patients’ characteristics are detailed in Table 2. A second set of five RCD1, ten RCD2
from Fondazione IRCCS Ca’ Granda Hospital was used for target expression analysis by immunohistochemistry
(IHC, Supplementary Table S1). RCD was diagnosed according to the Oslo definition [10] and recent updates [11].
Briefly, CD patients who showed absence of clinical remission after 1 year of a correct GFD verified by an expert
nutritionist and the maintenance of villous atrophy at histology suggested the presence of a refractory state. RCD2
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Table 1 Clinicopathological characteristics of the intestinal lymphomas studied for miRNA profiling
Clinical features Immunohistochemistry1
Molecular
features2
ID Gender Subtype CD Status3
OS
months CD2 CD3 CD4 CD5 CD7 CD8 CD20 CD30 CD56 CD103 β F1 TIA1
Granzyme
B Perforin KI67 EBV TCRγ
ITL1 F EATL yes 1 12 0 1 0 0 1 1 0 0 0 0 0 1 1 1 1 0 1
ITL2 M MEITL no 1 2.5 1 1 0 1 1 1 na na na na na na na na 0 na na
ITL4 M EATL yes 1 10 0 1 1 0 1 0 0 1 na na na na 1 na 1 na na
ITL5 F MEITL no na 1 1 0 0 1 1 0 0 1 0 1 1 na na na 0 0
ITL6 F EATL yes 1 4 0 1 0 0 1 1 0 1 0 1 0 1 0 1 1 0 0
ITL7 M EATL yes 1 2 na 1 na na na na 0 1 0 na 1 na 1 1 0 0
ITL8 M MEITL yes 1 1 1 1 0 1 1 1 0 0 1 1 0 1 0 1 1 0 1
ITL10 F MEITL no 1 6 1 1 0 0 1 1 0 0 1 0 1 1 0 1 1 0 1
ITL11 F EATL yes 1 7 1 1 1 0 1 0 0 1 0 1 0 1 1 1 1 0 0
ITL27 F EATL yes 0 60 0 1 0 0 1 0 0 1 0 0 0 1 1 1 1 0 na
ITL30 M EATL no 1 5 1 1 1 0 1 0 0 1 0 0 1 1 1 0 0 0
ITL35 M EATL yes 0 60 0 0 0 0 1 0 0 1 0 1 0 1 1 0 1 0 0
ITL37 F EATL yes 1 2 0 1 0 0 1 0 0 1 0 1 0 1 1 1 1 0 1
ITL39 M EATL yes 1 18 0 1 1 na 1 0 na 1 0 na 0 1 na 1 1 na 0
ITL41 M EATL yes 1 25 1 1 0 0 1 0 0 0 0 1 1 1 1 1 0 0 0
ITL45 F MEITL no 0 24 0 1 0 0 1 1 0 0 0 1 0 1 na 1 1 0 1
ITL47 M MEITL no 1 12 0 1 0 0 1 1 0 0 1 1 0 1 1 1 1 0 na
ITL53 F EATL yes 0 22 1 1 1 0 1 0 0 1 0 1 0 1 1 1 1 0 0
ITL56 M MEITL no na na 1 na na na na 0 na 1 na na na na na 1 na na
ITL57 F EATL no na 0 1 0 0 1 1 0 1 0 na 0 1 1 1 1 na 0
ITL60 M EATL yes na 1 1 1 1 1 0 na 1 0 na na 1 na 1 1 na na
10, absent; 1, present; na, information not available; for KI67 staining, ITL with a percentage of positive cells below 50% were considered 0.
2EBV, Epstein–Barr virus; TCRγ, clonality of T-cell receptor γ; 0, absent; 1, present; na, information not available.
30, censored; 1, deceased.
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Table 2 Clinicopathological characteristics of the CD patients studied for miRNA profiling
ID Gender Subtype1 Classification2 TCR-clonality3 Evolution to EATL Status
CD11 F Active 3b na No Alive
CD12 F Active 3a Polyclonal No Alive
CD13 M Active 3a na No Alive
CD14 F Active 3a na No Alive
CD15 F Remission na na No Alive
CD16 F Remission 0 na No Alive
CD17 F Remission 1 na No Alive
CD18 M Remission 0 na No Alive
CD19 F Remission 2 na No Alive
CD20 F At diagnosis 3a na No Alive
CD21 F At diagnosis 3a na No Alive
CD22 F At diagnosis 3c na No Alive
CD23 F At diagnosis 3c na No Alive
CD24 F At diagnosis 3a na No Alive
RCD17 F RCD1 3b na No Deceased
RCD18 F RCD1 3c na No Alive
RCD19 F RCD1 3c na No Alive
RCD20 M RCD1 3a na No Alive
RCD12 F RCD2 3b Monoclonal No Alive
RCD13 F RCD2 3a na No Alive
RCD14 F RCD2 3c Monoclonal No Alive
RCD15 M RCD2 3c Monoclonal Yes Deceased
RCD16 M RCD2 3c Monoclonal Yes Deceased
1Active, presence of villous atrophy in spite of GFD; remission, absence of villous atrophy after GFD; At diagnosis, newly diagnosed CD patient; RCD1,
refractory type 1 CD; RCD2, refractory type 2 CD.
2According to Marsh–Oberhuber criteria.
3TCR; na, not available information.
diagnosis was made if the following two criteria were present: (i) the presence at flow cytometry of a relevant (>20%)
quote of duodenal intraepithelial lymphocytes (IEL) with the aberrant phenotype (positive for intracytoplasmic CD3
and negative for surface CD3) and (ii) mono/oligoclonality for TCRγ. Conversely, the absence of these two markers
identified RCD1 condition.
The present study was carried out in accordance with the World Medical Association Declaration of Helsinki and
approved by the local Ethic Committee (IRB#278 2015). All subjects provided written informed consent.
Preclinical model of RCD
The TG mice that express human IL-15 specifically in enterocytes (T3b-hIL-15 Tg mice) have been previously de-
scribed [5,6]. Aged-matched non-TG littermates (WT) were used as control for baseline miRNA expression (calibra-
tor). Animal experiments were previously approved by the Institutional Animal Care and Use Committee [6]. Briefly,
animals at 11 and 13 weeks of age (n=4 mice per condition) were used. Formalin-fixed paraffin-embedded (FFPE)
blocks with small intestinal mucosa fromwild-type (WT), TG or TG treated with the pan-JAKi Tofacitinib were used
for miRNA profiling. miRNA data in TG or JAKi mice were expressed as differences with respect to the calibrator
(log2-transformed values).
RNA purification
Separation of lymphomatous from entherocyte component was achieved by laser-assisted microdissection
(LMD6000; Leica Microsystems) as described [12]. Then, total RNA was purified from all human or murine samples
using the MasterPure RNA Purification Kit (Epicentre, an Illumina company) followed by genomic DNA digestion
with RNase-Free DNase I (Epicentre) as previously described [7].
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Gene and miRNA expression analysis
The transcriptome of 18 ITL cases (12 EATL and 6MEITL) was analyzed using the cDNA-mediated Annealing Selec-
tion extension and Ligation (DASL) platform (Illumina) and 500 ng of DNA-free total RNA as described [8]. Then,
raw data were quantile-normalized and log2-transformed using the lumi package within Bioconductor environment
[13].
For miRNA profiling, 200 ng of DNA-free total RNA were reverse transcribed and pre-amplified using human or
rodent Megaplex Primers Pools A and B (Thermo Fisher Scientific). miRNA quantification was obtained using the
Taqman TLDA cards A and B as described [12]. Only miRNAs whith raw mean value minus one standard deviation
having<35Ct passed the filter and were included in the analyses. miRNA relative quantification (RQ) was achieved
using the global mean method followed by log2 transformation for normalization. When individual miRNAs were
analyzed, total RNA was reverse transcribed with specific primers and TaqMan assays were used for qPCR. In this
case, the mammary U6 ncRNA was used as reference transcript.
IHC
The presence of c-MYC (clone Y69, Dako, Agilent Technologies Inc.), phosphorylated-STAT3 at Tyr705 (clone D3A7,
Cell Signaling Technologies), SMAD3 (clone 2C12, Sigma–Aldrich), and MDM2 (clone IF2, Merck KGaA), was an-
alyzed in human tissue sections by IHC using the Dako Omnis or the Ventana Benchmark Ultra autostainer as
described [14]. Immunoreactivity was revealed using DAB as chromogen or the Ultraview Red Detection Kit and
staining of the lymphocytic infiltrate was separately scored as percentage of positive cells. When mice tissues were
processed for IHC, the Rodent blockM reagent (BioCare Medical, Pacheco, CA, U.S.A.) was added to the slides prior
to primary antibody as suggested by the manufacturer.
Fluorescence in situ hybridization
The genetic status of c-MYCwas analyzed in three RCD2 and five EATL samples from the validation series using flu-
orescence in situ hybridization (FISH) technique. Briefly, FFPE tissues underwent digestion using the Poseidon kit
(LeicaMicrosystems, Milan, Italy) and then were hybridized with an LSI-MYC dual color, break apart rearrangement
probe (Abbott Laboratories, Abbott Park, IL, U.S.A.) following manufacturer’s protocol. DAPI was used to counter-
stain nuclei. As positive control for c-MYC amplification we used a radiotherapy-associated angiosarcoma (RAS) of
the breast.
Data analysis
Gene or miRNA expression data were analyzed by both unsupervised and supervised test. Briefly, the Complex-
Heatmap package available in Bioconductor was used for hierarchical clustering analysis, and K-means clustering al-
gorithmwas used to visualize set of co-regulatedmiRNAs. Principal component analysis (PCA; https://cran.r-project.
org) was used to visualize patients’ distribution according to the miRNome or selected miRNAs as described [15].
Pearson analysis (R studio) was used to assess samples similarity using the Silhouette method. The non-negative
matrix factorization analysis (NMF) from Genepattern (https://cloud.genepattern.org/) was used for unsupervised
samples clustering. Lists of significant miRNAs were obtained using the Kolgomorov–Smirnov test and computing
the fold-change (Log2Ratio, L2R). All P-values were corrected formultiple comparisons using the false discovery rate
(FDR) approach. To identify ‘classifier’miRNAs,we used the decision tree-based classificationmethodRandomForest
available within R environment [16].
Receiver Operating Characteristic (ROC) curve and the Youden’s J statistic was used to identify cutoffs in CD56
gene expression to sort ITL cases into positive or negative groupwhen immunohistochemical evaluation of the protein
was missing. Correlation of molecular variables with patients’ survival was performed using Log-Rank test (MedCalc
software). Differences among samples’ groups were performed using Mann–Whitney U or Kruskal–Wallis test as
appropriate.
miRNAs’ targets were searched using the miRTargetLink Human tool (https://ccb-web.cs.uni-saarland.de/
mirtargetlink/), which provides list of experimentally validated miRNA targets and only genes predicted to be tar-
geted by the miRNA with ‘strong evidence’ were used for Gene Ontology and pathways analysis using STRING
(https://string-db.org/) [17].
All statistics were two-sided and P-values less than 0.05 were considered statistically significant unless otherwise
indicated.
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Figure 1. ITLs carry a distinctive miRNA signature in comparison with other PTCLs
(A,B) The miRNome was analyzed in different PTCL subtypes. Unsupervised NMF analysis sorted the samples into two main
groups (a), and all ITLs but one case were classified in the same cluster (b). (C) Heatmap of the top 50 miRNAs mostly expressed
by ITLs or by other PTCLs. Blue, low expression; Red, high expression. (D) Among the top miRNAs over-represented in ITL or other
PTCLs were respectively members of the C19MC cluster (namely miR-518f, miR-523 and miR-518b; top panel) or the lncRNA
MIR100HG-derived miRNA miR-100, and miR-125b (lower panel). Bars, mean +− standard error of the mean (SEM). TCL, T-cell
lymphoma.
Patient and public involvement statement
Patients and public were not involved in any phase of the research because of its retrospective nature. Indeed, all
experiments were performed on archival FFPE tissue blocks.
Results
ITLs are characterized by a unique miRNA profile with respect to other
types of PTCLs
We started our study looking at the global expression of miRNAs in different types of T-cell lymphomas, such as
PTCL-NOS, ALK-positive or negative anaplastic large cell lymphoma, AITL, EBV positive (EBVPOS) extranodal
NK/T-cell lymphoma and ITLs. By unsupervised NMF analysis, ITL showed a distinct miRNA profile in compar-
ison with other PTCLs (Figure 1A,B). Interestingly, the two EBVPOS-extranodal NK/T-cell lymphomas originated in
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the bowel also clustered together with ITLs. Looking at top miRNAs specifically enriched in ITLs or in the other
subtypes of PTCL (Figure 1C; Supplementary Table S2), we identified that the C19MCmiRNA cluster was expressed
more in intestinal lymphomas whereas the miRNAs transcribed from the MIR100HG lncRNA, namely miR-100,
let-7a-5p and miR-125b, were over-represented in PTCLs (FDR-adjusted P-value<0.05; Figure 1D).
c-Myc regulated miRNAs distinguish MEITL from EATL and are markers
of poor prognosis in EATL patients
Next, we interrogated the miRNome of ITL in depth. Based on the new WHO classification we sorted cases into
EATL or MEITL on the basis of on their morphology, immunophenotype and Ki67 index (Table 1) or CD56 ex-
pression at mRNA level if IHC was unavailable (Supplementary Figure S1A). The two EBVPOS-extranodal NK/T-cell
lymphoma cases were excluded from the analysis. At unsupervised level the miRNome was unable to distinguish
EITL from MEITL cases (Figure 2A). We therefore searched for differentially expressed miRNAs between the two
histotypes, and 29 miRNAs were identified (Supplementary Table S3 and Supplementary Figure S1B). Performing
hierarchical clustering of all samples with significant miRNAs, we observed that all MEITL but one grouped under
a specific cluster, whereas EATL showed a high degree of intertumor heterogeneity and clustered into three different
branches, designated as clusters A, B and C (Figure 2B). This organization of EATL in three principal subclusters was
also conserved when we reconsidered samples distribution using the totality of microRNAs in an unsupervised anal-
ysis (Supplementary Figure S1C). Among the significant miRNAs, 6 belonged to the c-Myc up-regulated miR-17/92
and its paralogs miR-106a/363 and miR-106b/25 miRNA clusters, namely miR-20b-5p, -19b-3p, -17-5p, -106a-5p,
-92a-3p and miR-19b-1-5p (Figure 1B) [18]. Besides being up-regulated in MEITL as compared with EATL, these
miRNAs showed differential expression within EATL grouped into the three subsets, with cluster-C EATL showing
miRNAs levels comparable with MEITL (Figure 2C). We then analyzed the expression of known c-Myc associated
transcripts [5] in MEITL and EATL grouped into the three subclusters (Supplementary Table S4). In agreement with
miRNA data, unsupervised analysis of c-Myc related transcripts distinguished EATL in clusters A and B from EATL
in cluster C, which grouped with MEITL (P=0.02 by Fisher’s exact test; Figure 2D). Specifically, the c-Myc activated
transcripts ENO1, RPL11, STAT3 and SMAD4 were expressed more in cluster C-EATL and MEITL than in EATL
from subclusters A or B (P<0.05 by Kruskal–Wallis test; Figure 2E). The activation of c-Myc signaling in cancer is
usually associated with poorer prognosis. Therefore we analyzed survival curves of EATL sorted into the three sub-
sets. As expected, patients belonging to cluster C had the worst prognosis (HR cluster C = 7.2; P=0.06; Figure 2F),
recapping the outcome of MEITL patients (Supplementary Figure S1D,E). Finally, we took advantage of a preclinical
model of EATL/RCD, i.e. the TG mice that express human IL-15 in enterocytes (T3b-hIL-15 Tg mice) [5,6] in or-
der to analyze c-Myc regulated miRNAs in the duodenum of animals treated (JAKi; Figure 2G) or not (TG; Figure
2G) with the pan-JAKi, Tofacitinib. Thirteen out of 18 miRNAs belonging to the miR-17 family were expressed in all
mice (72%). With the exception of miR-106b-3p and miR-93-3p, all the miRNA belonging to the miR-17 family were
decreased after the treatment (Figure 2G). This result, together with the observation that miR-17/92 miRNAs are
overexpressed in EATL with worse outcome, supports a role for the miR-17 family of miRNAs in EATL pathogenesis.
Random forest analysis identifies a signature of 38 miRNAs that defines
CD-associated ITL, RCD2 or RCD1 and classic CD
We then sought to investigate whether duodenal samples from patients with RCD, had a global miRNAs profile sim-
ilar to intestinal lymphomas, to PTCLs, or were unrelated to both neoplastic conditions. By unsupervised analysis,
RCD1 and RCD2 samples grouped together with intestinal lymphomas in two clusters separately from PTCL-NOS,
ALK-positive or negative anaplastic large cell lymphoma and AITL (Figure 3A). We then focused on patients with
previous or current history of CD and we analyzed if miRNAs were able to discriminate intestinal lymphomas from
RCD2, RCD1 or from less aggressive forms of CD (Tables 1 and 2). PCA showed that, globally, miRNAs discrim-
inated CD patients with intestinal lymphoma, or with RCD2, whereas patients with RCD1 were grouped with CD
subjects with less severe disease (Figure 3B). Therefore, we searched for miRNA signatures specific to the different
classes of disease using the Random Forest algorithm either separating (Figure 3C) or not (Figure 3D) RCD1 from
CD. Confirming what was observed at unsupervised analysis (Figure 3B), RCD1 could not be distinguished from
CD (Figure 3C; misclassification rate for RCD1 = 100%). Conversely, when RCD1 and CD were grouped in a single
class (CD RCD1) all cases were correctly classified by the algorithm, as well as 4 out 5 RCD2 and 12 out of 13 in-
testinal lymphomas (ITL-CD) (overall misclassification rate of 5.4%; Figure 3D). Top discriminating miRNAs were
then identified based on the MeanDecreaseGini (≥0.118) and P-value (<0.05; Figure 3E). According to these crite-
ria, 38 miRNAs were included in the classifier (Supplementary Table S5).When a similarity analysis between samples
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Figure 2. miR-17/92 and paralogs are overexpressed in MEITL and identify EATL with worse prognosis
(A) PCA shows that the miRNome does not distinguish EATL fromMEITL at unsupervised level. (B) Heatmap of significantly different
miRNAs in EATL and MEITL samples. When CD56 immunophenotype could not be detected by IHC, gene expression data (DASL)
were used for ITL classification. miRNA in bold are from the miR-17/92 cluster or paralogs. (C) The indicated miRNAs were analyzed
in the three EATL subgroups (identified in panel B) and in MEITL specimens. Bars, mean +− SD. (D,E) Transcripts known to take
part in c-MYC signaling were analyzed in EATL and MEITL. Unsupervised samples clustering (D) shows that, as for the miR-17/92,
cluster C-EATL andMEITL share similar gene expression patterns, and are enriched in the same branch of the dendrogram (P=0.02,
by Chi-square test). The expression of significantly different transcripts among EATL subsets, shows similar genes levels in cluster
C-EATL and MEITL (E). Box and whiskers represent lowest-to-highest and median values. Each dot is a sample. (F) Kaplan–Meier
curves of EATL sorted into the three different classes according to miR-17/92 miRNAs levels. HR, hazard ratio, 95% CI, 95%
confidence interval. Cl.C, cluster C-EATL. (G) The indicatedmiRNAs were analyzed in T3b-hIL-15 Tg trangenic mice treated (JAKi) or
not (TG) with the JAKi Tofacitinib. Aged-matched non-TG littermates were used as calibrator and data are expressed as differences
in respect to the calibrator (log2-transformed values). *, P=0.01; §, P=0.03; #, P=0.049 by Mann–Whitney U test. Bars represent
mean +− SEM (n=4) and each dot is a sample.
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Figure 3. Identification of a miRNA signature for classifying RCD2 apart from ITL or CD patients
(A) NMF analysis was performed using the miRNome from all PTCL types, ITL, RCD1 and RCD2. RCD1 and 2 samples cluster with
ITL and separately from PTCLs. (B) PCA with all miRNA was performed considering only CD patients with different diseases (CD,
RCD1 or 2, ITL). PC, principal component. (C,D) The random forest (RF) algorithm was used to identify miRNAs able to sort CD
patients with different diseases into separate classes. When the algorithm was asked to identify four groups of disease (ITL, RCD2,
RCD1, CD), a high misclassification rate was observed (C; 16.2%). When only three classes were considered (ITL, RCD2, RCD1
with CD), the misclassification rate dropped to 5.4% (D); one case with RCD2 and one ITL were classified as CD RCD1). OOB,
out of bag. (E) RF-top ‘classifier’ miRNAs according to three criteria: gini decrease, accuracy decrease and P-value. (F) Pearson’s
correlation analysis was performed with the RF-miRNA signature to evaluate samples’ similarity.
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was performed based on the 38 miRNAs-classifier, RCD2 showed to be more similar to CD and RCD1 cases than
to the majority of ITL-CD (Figure 3F). These data suggest that RCD2 is a distinct disease with a specific miRNA
dysregulation profile, but still retains greater similarity to CD than to lymphoma from a molecular perspective.
The miR-200 and miR-192/215 families are progressively lost in RCD2
and intestinal lymphomas
The 38-miRNAs signature was then visualized in all samples using heatmap, and miRNAs subgrouping was per-
formed using the k-means clustering algorithm. This analysis generated four miRNA subgroups in which k-means
cluster 1 and 2 included miRNAs underexpressed in ITL-CD cases while k-means cluster 3 and 4 included miRNAs
overexpressed in intestinal lymphomas of CD patients (Figure 4A). Interestingly, while k-means cluster 1 and 3 con-
tainedmiRNAs specifically dysregulated only in neoplastic samples, k-means cluster 2 and 4 includedmiRNAswhose
expression was similar both in ITL-CD and RCD2 cases as opposed to what was detected in RCD1 or CD patients
(Figure 4A). Among the top down-regulated miRNAs in ITL-CD and in ITL-CD and RCD2 were members of the
miR-200 andmiR-192/215 families (9 out of 24 transcripts; Supplementary Table S5).When bioinformatics prediction
of potential targets was performed (Supplementary Tables S6 and S7), cell cycle and cancers related pathways emerged
asmostly affected by k-means cluster 1 and 2miRNAs (Supplementary Tables S8 and S9 respectively and Supplemen-
tary Figure S2A,B) but transcriptional dysregulation in cancer, Th17 cell differentiation, p53 and TGF-β signaling
were more significantly affected by cluster 2 miRNAs (Supplementary Figure S2B and Supplementary Table S9). To
provide preliminary insights into dysregulation of these signaling in CD-related entheropathies, we first searched if
predicted targets were inversely correlated with k-means cluster 2 miRNAs in our series of CD-ITL. We confirmed
that SMAD3, Cdc42, and MDM2 could be targeted by at least one miRNA from k-means cluster 2 (Figure 4B and
Supplementary Figure S3A). Next, we looked at targets protein expression in an independent set of EATL, RCD2 and
RCD1 samples (Supplementary Table S1) by IHC. In line with miRNA data, we found that SMAD3 expression was
progressively increased in T cells of RCD2 and EATL tissues compared with RCD1 (Figure 4C,D and Supplementary
Figure S3B,C), whereas MDM2 was predominantly expressed in RCD2 compared with RCD1 or EATL (Figure 4E).
Finally, k-means cluster 1 and 2 miRNAs down-regulation was partially reversed in the IL15-TGmice treated with
the pan-JAKi (Supplementary Figure S3D,E). In line with this, MDM2 and SMAD3 proteins expression was lower in
the intestinal mucosa of mice treated with the JAKi (Supplementary Figure S3F,G). Altogether, these data point to a
role for the miR-200 and miR-192/215 miRNA families in the progression of CD from refractory disease toward a
neoplastic stage at least in part through the regulation of SMAD3/MDM2 signaling.
The oncomiRNAs belonging to the miRNA clusters miR-17/92 and C19MC
are up-regulated in RCD2 and ITL-CD
Among the miRNAs significantly overrepresented in both lymphomatous and RCD2 samples (k-means cluster
4) were members of the miR-17/92 cluster (namely miR-18b-5p and miR-363-3p) and C19MC miRNA cluster
(namely miR-517c-3p and miR-523-3p), two recognized families of onco-miRNAs. Among the pathways activated
by miR-17/92 miRNAs is c-Myc [19] and a recent report also described the existence of an oncogenic circuit between
C19MC and n-MYC in embryonal tumors with multilayered rosettes (ETMRs) [20]. Moreover, k-means cluster 4
miRNAs were inversely correlated with c-Myc mRNA in EATL (Figure 5A). Therefore, we analyzed c-Myc and ac-
tivated Signal Transducers and Activators of Transcription 3 (STAT3 phosphorylated at Tyr705 residue) in duodenal
biopsies from celiac patients with EATL, RCD2 or RCD1. While c-Myc was overexpressed mainly in lymphomas
(Figure 5B,C), STAT3 was significantly more activated in the aberrant lymphocytic compartment of RCD2 and EATL
than in RCD1 (Figure 5B,C and Supplementary Figure S4A). This observation is in line with the fact that STAT3
acts upstream of Myc and suggests that STAT3 activation and nuclear accumulation precedes c-Myc overexpression
[21,22]. Accordingly, activated STAT3was decreased upon JAK signaling inhibition in IL15-TGmice (Supplementary
Figure S4B). Finally, FISH analysis of c-MYC status in EATL and RCD2 tissues evidenced that a fraction of EATL cells
display c-MYC gene amplification (range 1–17%) and that this mechanism is not clonal. No RCD2 sample showed
gain in c-MYC copies (Figure 5D and Supplementary Figure S5A–C). Finally, c-MYC amplification did not consis-
tently explained protein overexpression detected in EATL, as there was no direct association between FISH and IHC
quantification of positive nuclei (Figure 5E). Therefore, these data suggest that an oncogenic network between Myc
signaling andmiRNAs belonging to the C19MC andmiR-17/92 clusters possibly promotes neoplastic transformation
of aberrant T lymphocytes in the enteric mucosa of RCD patients (Figure 6).
1160 © 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
D
ow
nloaded from
 https://portlandpress.com
/clinsci/article-pdf/134/10/1151/881988/cs-2020-0032.pdf by guest on 29 July 2020
Clinical Science (2020) 134 1151–1166
https://doi.org/10.1042/CS20200032
Figure 4. Progressive miR-200 and miR-192/215 miRNAs decrease with SMAD3 and MDM2 up-regulation characterizes
RCD2 and ITL
(A) Heatmap of the RF-signature of 38 miRNAs in patients with previous or current history of CD with ITL, RCD1, RCD2 or different
stages of CD. K-means clustering analysis was performed to identify groups of co-regulated miRNAs. a-CD, active CD despite
GFD; r-CD, CD in remission after GFD. (B) Predicted protein targets of k-means cluster 2 miRNAs (identified using miRTargetLink
Human algorithm; Supplementary Table S7) and their associated signaling were visualized and analyzed using STRING database.
The top predicted pathways (from KEGG) specific to k-means cluster 2 miRNAs are also indicated (Supplementary Table S9 for the
complete list). (C) Inverse correlation between the indicatedmiRNA and the predicted target was performed in ITL-CD for which both
expression data were available (n=12). ρ, Spearman’s coefficient of rank correlation. (D) Nuclear localization and protein expression
of SMAD3 was evaluated in a second series of RCD1, RCD2 and EATL cases (Supplementary Table S1 for details) by IHC. Bottom,
quantification of SMAD3-positive cells. *, P=0.03 **; P=0.009; #, P=0.003 by Mann–Whitney’s U test. Scale bar, 100 μm. (E) Double
IHC for SMAD3 (marked in brown) and CD7 (marked in red) in representative RCD2 and EATL cases showing co-expression of the
two markers. Scale bars, 100 μm. (F) Nuclear localization and protein expression of MDM2 was evaluated in the second series of
RCD1, RCD2 and EATL cases (see Supplementary Table S1 for details) by IHC. Bottom, quantification of MDM2-positive cells. §,
P=0.01; *, P=0.04 by Mann–Whitney’s U test. Scale bar, 100 μm.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 1161
D
ow
nloaded from
 https://portlandpress.com
/clinsci/article-pdf/134/10/1151/881988/cs-2020-0032.pdf by guest on 29 July 2020
Clinical Science (2020) 134 1151–1166
https://doi.org/10.1042/CS20200032
Figure 5. Up-regulation of C19MC and miR-17/92 miRNAs in RCD2 and ITL with CD correlates with c-MYC/STAT3 signaling
activity
(A) Inverse correlation between the indicatedmiRNAs and cMYCmRNAwas performed in and ITLwith CD for which both expression
data were available (n=12). The Spearman’s rank correlation coefficients are: ρ = −0.79 (miR-18b-5p), ρ = −0.67 (miR-363-3p), ρ =
−0.75 (miR-517c-3p) and ρ = 0.07 (miR-523-3p). (B,C) Nuclear localization and protein expression of c-MYC and phosphorylated
STAT3 at Tyr705 (pSTAT3) was evaluated in the second series of RCD1, RCD2 and EATL cases (Supplementary Table S1 for details)
by IHC and the percentage of positive cells was quantified (C). Scale bars, 100 μm. §, P=0.001; ◦, P=0.016; #, P=0.005; *, P=0.03;
**, P=0.008 by Mann–Whitney’s U test. (D) c-MYC analysis by FISH (overlay) with a dual color break apart probe is shown for
representative EATL and RCD cases. Nuclei with gene amplification are circled in white, while blue circles indicate IEL present
within RCD2 mucosa. Single-color pictures are provided in Supplementary Figure S5B,C. Scale bar, 10 μm. Right, quantification
in the indicated sample type of nuclei with normal (i.e. =2) or amplified (>2 copies per nuclei) c-MYC. (E) Correlation between
c-Myc amplification (percentage of positive nuclei from FISH analysis) and protein expression (percentage of positive nuclei from
IHC staining) was evaluated in each EATL case (n=4). ITL-CD, ITL with CD.
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Figure 6. Schematic of the proposed model
Discussion
In the present study, we provide initial characterization of miRNAs and associated signaling pathways specific to
ITLs and refractory type-2 CD, a preneoplastic condition that affects approximately 5–10% of all CD patients. We
have identified that ITLs have a specific miRNA signature centered on overexpression of the chromosome 19miRNA
cluster C19MC with respect to other PTCLs. We also found that another oncogenic miRNA cluster, the miR-17/92,
is overexpressed in MEITL as compared with EATL, and in EATL patients with poorer prognosis. Next, we have
focused only on CD patients and searched for miRNAs potentially able to discriminate among CD, RCD and intesti-
nal lymphoma (ITL-CD) diseases. Our data propose that a coordinated repression of oncosoppressive miR-200 and
miR-192/215 coupled with the overexpression of the two oncogenic miRNA clusters C19MC and miR-17/92 might
promote and sustain the neoplastic transformation of the aberrant intraepithelial T-cell clone in RCD2 patients. At
the protein level this is accompanied by increased nuclear SMAD3 and MDM2 expression, which is paralleled by
STAT3 activation and eventually results in c-Myc overexpression into full-blown lymphoma. To better understand if
these miRNAs could have a pathogenic role in intestinal lymphomagenesis, we analyzed their expression in the IL-15
TG mouse model either left untreated or after treatment with the pan-JAKi Tofacitinib. This mouse model recapitu-
lates, at least in part, the inflammatory state characteristic of human RCD. The IL-15 TG mice do not display gluten
sensitivity, yet they strikingly recapitulate many of the intestinal pathologic features seen in CD patients. The IL-15
transgene in these mice are expressed from a mouse enterocyte specific T3b promoter that is active throughout the
small intestines, yet the inflammatory pathologic lesions are anatomically confined to the duodeno–jejunal region of
the small intestines. Furthermore, as seen in CD patients, in addition to the extensive localized blunting and atrophy
of intestinal villi in the proximal small intestines, there is marked accumulation of plasma cells in the underlying lam-
ina propria along with hypergammaglobulinemia and the presence of autoantibodies against tissue-transglutaminase
2 thus collectively representing some of both T- and B-cell-mediated effects seen in CD. The treatment of these mice
with tofacitinib, a pan JAKi that abrogates IL-15 signaling, results in the complete reversal of pathologic manifesta-
tions in the proximal small intestines [6].
In support of our findings, the miR-200 and miR-192/215 levels were decreased while miR-17/92 miRNAs were
up-regulated in the mice small bowel. Further, JAK inhibition partly reverted the expression of RCD2-dysregulated
miRNAs. Interestingly Tofacitinib is already used in other inflammatory diseases [3] including ulcerative colitis and
Chron’s disease [23] and could represent a novel therapeutic for RCD2. Lastly, the similarity analysis of the sam-
ples based on the identified miRNA signature revealed that RCD2 are more close to RCD1 than to lymphomas.
This supports the concept that RCD2 are not yet full-blown lymphomas and suggest that target treatments, such
as IL15/STAT3/JAK blocking, might revert RCD2 to less severe RCD1 or CD stages.
All these miRNAs have been previously documented as crucial players in tumorigenesis and matrix remodeling
[24,25] and a role for miR-192/215 family in CD has been previously described [7,26]. Furthermore, the analysis of
co-upregulated miRNAs in RCD2 and ITL-CD indicated once again a role for C19MC and miR-17/92 miRNAs in
sustaining the tumorigenesis of aberrant T cells in CD. Both miRNA families are known to be part of an oncogenic
feedback loop with MYC [20,27]. In line with this, analysis of nuclear expression of c-Myc or its upstream regulator
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STAT3 [21,22] in RCD1, RCD2 and EATL specimens has showed that activated STAT3 is a feature shared by RCD2
and EATL cases, whereas c-Myc is mainly overexpressed in lymphomas where it is also amplified in a portion of
neoplastic cells. Interestingly, JAK1 or STAT3 activating mutations have been previously described in RCD2 as major
drivers of intraepithelial lymphocytes neoplastic transformation [28]. Moreover, pro-tumorigenic circuits between
miRNAs and c-Myc has been described in solid tumors and in lymphomas [29] as well as at different stages of tumor
initiation and progression [27].
Although CD rarely evolves into RCD, the incidence of subjects with CD is increasing worldwide. GFD
is the only approach to control CD and RCD2 patients are usually treated with the general chemotherapeu-
tic/immunosuppressant cladribine, [1] or with autologous hemopoietic stem cell transplantation [3]. However a ra-
tionale to guide a personalized approach for patients’ management or treatment does not exists to date.
In this scenario the identification of novel biomarkers to guide patients’ stratification into risk categories is urgently
needed in order to transform the general approach to CD patients’ management into a personalized one. Despite
our results provide a preliminary overview of deregulated miRNAs/targets circuits, they collectively represent an
initial step in the understanding of molecular pathogenesis of RCD2 and related EATL and potentially contribute in
designing a personalized therapeutic approach for these diseases.
Clinical perspectives
• RCD2 and EATL are rare but deadly complications of CD. Although initial knowledge of intraepithe-
lial T-cells transformation has been acquired, the molecular determinants that contribute to these
diseases remain poorly defined.
• Here we show that deregulation of the c-MYC-related miRNA cluster miR17/92 and of miR-200 and
miR-192/215 families occurs in the transition from indolent CD to RCD2 and EATL. The miRNAs
targeting SMAD3, MDM2 and activated STAT3 are more expressed in RCD2 and EATL with respect
to RCD1 whereas c-Myc is expressed mostly by EATL. In the TG mouse model of RCD2, these
miRNAs are perturbed and treatment with a JAKi partially reverts miRNAs-targetderegulation in mice
intestine.
• Our results provide novel insights into miRNAs-target proteins circuits involved in the neoplastic
transformation of aberrant intraepithelial T cells and provide preliminary evidence about molecular
mechanism of JAKi in RCD2.
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